Search research articles
Contact Us
Filters
Showing results (121-130 of 209) with videos related to
Page
of 21
Sort By:
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
January 29, 2021
The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1
Hui Li, Xinwei Kuang, Long Liang, et al.
BMC Cancer
|
March 24, 2018
The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues
Nong Yang, Yi Li, Zhidong Liu, et al.
Chinese Medical Journal
|
December 22, 2025
First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation
Baohui Han, Solange Peters, Anh Tuan Le, et al.
Journal of Hematology & Oncology
|
January 5, 2025
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, et al.
Signal Transduction and Targeted Therapy
|
August 13, 2023
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
Yunpeng Yang, Jie Min, Nong Yang, et al.
JAMA Network Open
|
March 20, 2020
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial
Xiangyu Zhang, Yi Xiong, Qing Xia, et al.
JAMA Oncology
|
April 1, 2021
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
Jie Wang, Shun Lu, Xinmin Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2024
Efficacy and Safety of Taletrectinib in Chinese Patients With <i>ROS1+</i> Non-Small Cell Lung Cancer: The Phase II TRUST-I Study
Wei Li, Anwen Xiong, Nong Yang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 2, 2023
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer
Liang Zeng, Yuling Zhou, Qinqin Xu, et al.
Med (New York, N.Y.)
|
March 23, 2024
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
Liang Zeng, Lianxi Song, Li Liu, et al.
Page
of 21
Search research articles
Search
Showing results (121-130 of 209) with videos related to
Sort By:
Page
of 21
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
January 29, 2021
The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1
Hui Li, Xinwei Kuang, Long Liang, et al.
BMC Cancer
|
March 24, 2018
The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues
Nong Yang, Yi Li, Zhidong Liu, et al.
Chinese Medical Journal
|
December 22, 2025
First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation
Baohui Han, Solange Peters, Anh Tuan Le, et al.
Journal of Hematology & Oncology
|
January 5, 2025
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, et al.
Signal Transduction and Targeted Therapy
|
August 13, 2023
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
Yunpeng Yang, Jie Min, Nong Yang, et al.
JAMA Network Open
|
March 20, 2020
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial
Xiangyu Zhang, Yi Xiong, Qing Xia, et al.
JAMA Oncology
|
April 1, 2021
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
Jie Wang, Shun Lu, Xinmin Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2024
Efficacy and Safety of Taletrectinib in Chinese Patients With <i>ROS1+</i> Non-Small Cell Lung Cancer: The Phase II TRUST-I Study
Wei Li, Anwen Xiong, Nong Yang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 2, 2023
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer
Liang Zeng, Yuling Zhou, Qinqin Xu, et al.
Med (New York, N.Y.)
|
March 23, 2024
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
Liang Zeng, Lianxi Song, Li Liu, et al.
Page
of 21